MEI Pharma, Inc. (MEIP)
NASDAQ: MEIP · IEX Real-Time Price · USD
4.000
+0.050 (1.27%)
At close: Mar 28, 2024, 4:00 PM
4.070
+0.070 (1.75%)
After-hours: Mar 28, 2024, 4:30 PM EDT
MEI Pharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for MEI Pharma stock have an average target of 43.5, with a low estimate of 7.00 and a high estimate of 80. The average target predicts an increase of 987.50% from the current stock price of 4.00.
Analyst Consensus: Buy
* Price targets were last updated on Feb 14, 2024.
Analyst Ratings
The average analyst rating for MEI Pharma stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 6 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Stifel | Stifel | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +75.00% | Feb 14, 2024 |
Stifel | Stifel | Hold Maintains $10 → $9 | Hold | Maintains | $10 → $9 | +125.00% | Sep 27, 2023 |
Brookline Capital | Brookline Capital | Strong Buy Maintains $80 | Strong Buy | Maintains | $80 | +1,900.00% | May 23, 2023 |
Stifel | Stifel | Hold Maintains $0.5 → $10 | Hold | Maintains | $0.5 → $10 | +150.00% | May 12, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $100 → $40 | Strong Buy | Maintains | $100 → $40 | +900.00% | Feb 13, 2023 |
Financial Forecast
Revenue This Year
66.69M
from 48.82M
Increased by 36.62%
Revenue Next Year
6.38M
from 66.69M
Decreased by -90.44%
EPS This Year
3.35
from -4.78
EPS Next Year
-5.97
from 3.35
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 68.7M | 13.1M | 26.3M | 26.3M | 26.3M |
Avg | 66.7M | 6.4M | 25.5M | 25.5M | 25.5M |
Low | 64.0M | n/a | 24.5M | 24.5M | 24.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 40.8% | -80.3% | 311.8% | 2.9% | 2.9% |
Avg | 36.6% | -90.4% | 300.0% | - | - |
Low | 31.1% | - | 284.3% | -3.9% | -3.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 3.50 | -5.23 | -3.73 | -1.06 | -0.98 |
Avg | 3.35 | -5.97 | -3.62 | -1.03 | -0.95 |
Low | 3.18 | -6.59 | -3.48 | -0.99 | -0.91 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.